This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: Scientists Seek One Vaccine for Many Coronaviruses
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > Scientists Seek One Vaccine for Many Coronaviruses
Business

Scientists Seek One Vaccine for Many Coronaviruses

Editorial Board Published October 4, 2021
Share
Scientists Seek One Vaccine for Many Coronaviruses
SHARE

An emerging-infectious-diseases researcher with the U.S. Army, Dr. Modjarrad is pursuing a vaccine to protect against a range of coronaviruses that cause disease in humans—including Covid-19 variants that might elude today’s vaccines.

Contents
Kayvon Modjarrad’s research team is one of roughly 20 groups around the world working on pan-coronavirus vaccines.A leutralizing antibody MERS test at the International Vaccine Institute in Seoul.David Martinez in a lab at the University of North Carolina at Chapel Hill in June.Newsletter Sign-upCoronavirus Briefing and Health WeeklyCovid-19 Vaccines

The goal is to prevent the next new one from spreading around the globe. Such a shot might even stop coronaviruses that cause some common colds.

His research team is one of roughly 20 groups around the world working on so-called universal, or pan-coronavirus, vaccines: shots that would block many related viruses at once, including ones that have yet to infect anyone. After years of battling Ebola, Zika, H1N1 pandemic flu and other new pathogens, Dr. Modjarrad and other emerging-disease experts say they want to have a vaccine in hand to blunt the next new pathogen to come along, whatever it may be.

Kayvon Modjarrad’s research team is one of roughly 20 groups around the world working on pan-coronavirus vaccines.

Photo: Arlen Caplan and Mike Walters

“It’s our way out not just of this pandemic but this cycle of epidemics,” said Dr. Modjarrad, director of the emerging-infectious-diseases branch of the Walter Reed Army Institute of Research in Silver Spring, Md.

Three deadly new coronaviruses emerged in the past 18 years, including the virus that causes Middle East respiratory syndrome or MERS, and scientists warn another is likely. Many animals, including bats and rabbits, carry coronaviruses that can spread to humans. Millions of people around the world are being exposed to the pandemic virus, SARS-CoV-2, raising the risk that new, vaccine-resistant variants will arise, scientists say.

“We need to work proactively on these viruses and many, many others,” said David Veesler, a University of Washington School of Medicine biochemist whose lab is testing an experimental vaccine against a group of coronaviruses.

Scientists have spent years trying to develop a universal vaccine against influenza—without success yet. Coronaviruses, which mutate less often and have fewer distinct lineages, may be an easier target. But scientists say it could take years to develop one that protects against most of the coronaviruses that infect humans, with many challenges along the way.

Recent studies have shown that the effectiveness of Covid-19 vaccines is decreasing, though experts say the shots still work well. WSJ explains what the numbers mean and why they don’t tell the full story. Photo illustration: Jacob Reynolds/WSJ

The Coalition for Epidemic Preparedness Innovations, an Oslo-based organization that funds development of vaccines for epidemic diseases, is investing $200 million in grants for early-stage development of vaccines that protect broadly against dangerous coronaviruses. The U.S. National Institute of Allergy and Infectious Diseases, whose scientists are studying ways to make coronavirus vaccines, is awarding a further $95 million to other researchers, including $36 million to teams at Duke University, the University of Wisconsin, Madison and Brigham and Women’s Hospital in Boston.

Several companies are developing multivalent Covid-19 vaccines, which would target SARS-CoV-2 variants. The Biden administration and other funders should give priority to the development of shots that would broadly protect against these variants, said Eric Topol, director of the Scripps Research Translational Institute in La Jolla, Calif. “What we really need is a global collaborative effort,” he said.

“‘You have to prove that you can get to the moon before you try to go to Mars.’”

— Kayvon Modjarrad, Walter Reed Army Institute of Research

The vaccines now in development wouldn’t protect against all coronaviruses. The viruses are quite distinct from one another, making it a scientific challenge to create one vaccine that targets them all. Most researchers are focusing first on vaccines against sarbecoviruses, the group of greatest concern because it includes the pathogens behind Covid-19 and severe acute respiratory syndrome, or SARS.

If they are able to successfully create a sarbecovirus vaccine, then the next step is making vaccines that block betacoronaviruses, which include sarbecoviruses and the virus that causes MERS, which was first detected in 2012 and has about a 35% mortality rate. The group also includes two viruses that cause common colds.

“You have to prove that you can get to the moon before you try to go to Mars,” Dr. Modjarrad said.

Recent studies of antibodies in people infected with SARS-CoV-2 are helping to speed vaccine development, said Dennis Burton, an immunologist at Scripps Research. He and other researchers have identified “broadly neutralizing antibodies” that ward off both the pandemic virus and close viral cousins. Vaccines can then be developed that generate those antibodies when delivered into patients, he said.

A leutralizing antibody MERS test at the International Vaccine Institute in Seoul.

Photo: ed jones/Agence France-Presse/Getty Images

To create a universal vaccine, researchers look for portions of viral pathogens that are the same, or conserved, on related viruses. Many are focusing on the spike protein of the coronaviruses they are targeting, which juts out from the surface of the virus and enables it to latch on to and infect human cells.

The U.S. Army’s Dr. Modjarrad and his colleagues recently tested an experimental vaccine consisting of copies of a SARS-CoV-2 spike protein attached to a soccer-ball-shaped nanoparticle made of ferritin, an iron-storing blood protein. The vaccine protected macaques against the original pandemic virus, the researchers reported. The blood serum of the vaccinated macaques also fought off all the major SARS variants, Dr. Modjarrad said.

The researchers are now analyzing data from an early-stage clinical trial of the vaccine in humans, Dr. Modjarrad said, and testing in mice a similar vaccine meant to protect against a larger number of betacoronaviruses, including the virus that causes MERS.

David Martinez, a postdoctoral fellow at the Gillings School of Global Public Health at the University of North Carolina at Chapel Hill, began designing a vaccine against SARS-like viruses in April 2020 as the pandemic took hold in the U.S. “I thought, we need to start thinking about preventing SARS 3,” he said.

David Martinez in a lab at the University of North Carolina at Chapel Hill in June.

Photo: Jon Gardiner/UNC-Chapel Hill

He and his colleagues used messenger RNA, as Moderna Inc. and Pfizer Inc. and BioNTech SE did with their Covid-19 vaccines. Rather than genetic material from one coronavirus, they stitched together genetic codes from pieces of spike proteins of four SARS-like viruses: SARS-CoV, SARS-CoV-2 and two bat viruses.

Dr. Martinez had to wait until November for the hybrid vaccines to be produced, because a critical component also needed for the Pfizer and Moderna vaccines was in short supply. When the experimental vaccine was tested on mice, it protected them against Covid-19 variants, bat coronaviruses and other viruses.

The research team is seeking funding for an early-stage clinical trial in humans and is developing a vaccine against MERS and related betacoronaviruses, Dr. Martinez said.


Newsletter Sign-up

Coronavirus Briefing and Health Weekly

Get a morning briefing about the coronavirus pandemic three times a week and a weekly Health newsletter when the crisis abates.


At the University of Washington, Dr. Veesler and his colleagues created a Covid-19 vaccine from a virus-like nanoparticle studded with copies of the portion of the virus’s spike protein that binds to a receptor on human cells. That vaccine is now in late-stage clinical trials.

After identifying several broadly neutralizing antibodies against SARS-like viruses, the researchers set out to design a “version 2.0” of their vaccine, Dr. Veesler said. They attached to the nanoparticle copies of pieces of the spike protein from SARS-CoV-2 and three similar viruses: the one that causes SARS and two bat coronaviruses. When tested in mice, the vaccine showed it could provide broad protection against SARS-like viruses.

The team is now refining the vaccine and plans further tests.

The researchers also identified some antibodies that fight off a wider range of betacoronaviruses, including the one that causes MERS, Dr. Veesler said. But there are challenges to overcome: The antibodies are one-half to one-third as potent as other antibodies, and less common, he said.

The antibodies are “paving the way to design pan-coronavirus vaccines,” he said. “But we are not yet there.”

Covid-19 Vaccines

Write to Betsy McKay at betsy.mckay+1@wsj.com

Copyright ©2021 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article China Evergrande Unit Flags Possible Takeover Bid China Evergrande Unit Flags Possible Takeover Bid
Next Article Crypto Boom, Retail Investors Fuel Rise in Over-the-Counter Stocks Crypto Boom, Retail Investors Fuel Rise in Over-the-Counter Stocks

Editor's Pick

TLI Ranked Highest-Rated 3PL on Google Reviews

TLI Ranked Highest-Rated 3PL on Google Reviews

EXTON, PA — Translogistics, Inc. (TLI), a trailblazer in the 3PL and managed logistics space since its founding in 1994,…

By Editorial Board 12 Min Read
Gaetano Ori Saitta: The Visionary Trader Behind the Dubai Indicator
Gaetano Ori Saitta: The Visionary Trader Behind the Dubai Indicator

In the world of trading and financial innovation, few names stand out…

3 Min Read
Meet the Preakness Stakes horses working within the 2025 race
Meet the Preakness Stakes horses working within the 2025 race

The Preakness Stakes has a area of 9 horses set to race…

8 Min Read

Oponion

7 Greatest Blue Cologne For Males – Refined Scents For 2024 | Fashion

7 Greatest Blue Cologne For Males – Refined Scents For 2024 | Fashion

A blue cologne is a social signifier. And really very…

October 7, 2024

Jennifer Aniston & Pedro Pascal: Are They Relationship?

Studying Time: 3 minutes Are Jennifer…

March 24, 2025

Kroger CEO resigns after board investigation into his ‘private conduct’

Authorities waste, DOGE, inflation Kroger Co.…

March 3, 2025

Virginia Giuffre: Epstein Sufferer’s Father Says She Did not Commit Suicide, ‘Somebody Acquired to Her’

Studying Time: 3 minutes Giuffre —…

May 1, 2025

Natalie Pleasure: Nick Viall’s Spouse Reveals Second Miscarriage, Simply Months After Her First

Studying Time: 2 minutes Simply months…

March 23, 2025

You Might Also Like

Joseph Safina’s Vision for Empowered Entrepreneurship in the Age of AI and Acquisitions
BusinessTrending

Joseph Safina’s Vision for Empowered Entrepreneurship in the Age of AI and Acquisitions

In an era where ChatGPT can write marketing plans, and billion-dollar startups are snapped up before their founders can print…

6 Min Read
How Good Agriculture Can Make the most of a Satellite tv for pc API for Earth Commentary
Business

How Good Agriculture Can Make the most of a Satellite tv for pc API for Earth Commentary

The agricultural sector is present process a seismic shift, induced by the fusion of digital applied sciences like IoT, AI,…

9 Min Read
Soracom and Marubeni Announce Strategic IoT Collaboration and Conform to Set up Joint Enterprise
Business

Soracom and Marubeni Announce Strategic IoT Collaboration and Conform to Set up Joint Enterprise

New group will assist IoT MVNO capabilities in Japan and past Soracom, Inc., a world IoT platform supplier with full…

3 Min Read
Semtech Strengthens International IoT Connectivity Safety with AI-enabled Community Operations
Business

Semtech Strengthens International IoT Connectivity Safety with AI-enabled Community Operations

Actual-time Menace Detection Delivers 99.95% Uptime in 2024 Whereas Stopping Fraud Throughout Related Gadgets Semtech Company, a number one supplier…

2 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?